Barclays Trims IQVIA (NYSE:IQV) Target Price to $255.00

IQVIA (NYSE:IQV) had its price target reduced by Barclays from $275.00 to $255.00 in a research note issued to investors on Friday, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Several other research analysts have also commented on IQV. The Goldman Sachs Group assumed coverage on IQVIA in a report on Thursday, June 6th. They set a buy rating and a $270.00 price target on the stock. Evercore ISI reduced their price objective on shares of IQVIA from $275.00 to $250.00 and set an outperform rating on the stock in a report on Friday, May 3rd. Truist Financial reduced their price objective on shares of IQVIA from $297.00 to $292.00 and set a buy rating on the stock in a report on Friday, May 3rd. Robert W. Baird reduced their price objective on shares of IQVIA from $254.00 to $245.00 and set a neutral rating on the stock in a report on Friday, May 3rd. Finally, StockNews.com lowered shares of IQVIA from a buy rating to a hold rating in a report on Friday, June 21st. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, IQVIA presently has a consensus rating of Moderate Buy and an average price target of $257.73.

IQVIA Trading Down 0.6 %

Shares of IQV opened at $211.44 on Friday. IQVIA has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The firm’s fifty day moving average is $223.93 and its two-hundred day moving average is $230.18. The stock has a market cap of $38.52 billion, a PE ratio of 28.89, a price-to-earnings-growth ratio of 1.93 and a beta of 1.53.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Research analysts forecast that IQVIA will post 10.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Institutional investors and hedge funds have recently made changes to their positions in the stock. Los Angeles Capital Management LLC grew its position in shares of IQVIA by 17.5% during the fourth quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after buying an additional 17,677 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock valued at $532,070,000 after purchasing an additional 93,194 shares in the last quarter. Cadian Capital Management LP acquired a new position in IQVIA in the fourth quarter valued at approximately $70,108,000. Nomura Holdings Inc. acquired a new position in IQVIA in the fourth quarter valued at approximately $857,000. Finally, International Assets Investment Management LLC acquired a new position in IQVIA in the fourth quarter valued at approximately $13,759,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.